Proteins.1 is a Finnish biotech startup on a mission to make diseases detectable years before symptoms appear — when treatment is most effective and survival rates are highest. The Problem For diseases like cancer and Alzheimer's, the body releases early warning proteins into the bloodstream long before any clinical symptoms emerge. The problem is that these signals are so faint that today's blood tests simply cannot detect them. By the time a diagnosis is made, the disease has often already progressed to a stage where treatment options are limited and outcomes are far worse. Our Solution We've developed a breakthrough technology called Affinity-Mediated Transport (AMT) — think of it as bringing PCR-like amplification to proteins. Just as PCR revolutionized the detection of genetic material, our platform makes individual disease-signaling proteins visible from a standard blood sample, at sensitivities up to 1,000 times beyond what current gold-standard diagnostics can achieve. The technology originated at VTT Technical Research Centre of Finland, has been validated through EU breakthrough innovation funding, and is protected by granted patents in both the EU and the US. Where We Are Founded in 2025 and backed by €4.7M in pre-seed funding from Lifeline Ventures and Cloudberry Ventures, we are a team of deep-tech founders, engineers, and scientists based in Espoo, Finland — building the next generation of diagnostic instruments that could fundamentally change how the world detects and treats serious disease.